Aurinia Pharmaceuticals (AUPH) Tops Q3 EPS by 8c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $40.8 million versus the consensus estimate of $38.44 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Investing.com’s stocks of the week